Ask AI
ProCE Banner Series

An Update on Bladder Cancer: New Current Standards, Future Perspectives, and Unsolved Questions

Join us for a live, interactive webinar on optimal therapeutic approaches to managing patients with bladder cancer including those with non-muscle invasive disease, muscle invasive bladder cancer, or advanced bladder cancer. Experts on bladder cancer will explore current treatment paradigms, discuss novel therapies, and highlight unsolved questions.

  ANCC
  | AAPA
  | AMA
  | ACPE
Who Should Attend

This educational program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with bladder cancer

All Events

An Update on Bladder Cancer: New Current Standards, Future Perspectives, and Unsolved Questions

Past Events

April

13

2023

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Target Audience
This educational program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with bladder cancer 

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with bladder cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply the latest risk stratification guidelines to individualize treatment options for non-muscle invasive bladder cancer
  • Plan adjuvant therapy for patients with high-risk bladder cancer following radical resection
  • Integrate predictive biomarkers into the selection and sequencing of treatment for advanced bladder cancer
  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with urothelial carcinoma considering the available evidence and patient and disease characteristics
  • Identify patients with bladder cancer who may be eligible for enrollment in ongoing clinical trials actively investigating targeted systemic therapies and immune checkpoint inhibitor–based combination regimens for patients across the disease spectrum

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy Continuing Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit.

Universal Activity Number – JA4008196-0000-23-028-L01-P 

Upon successfully completing the activity and evaluation form, transcript information will be sent to NABP CPE Monitor Service within 60 days.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Physician Associate/Physician Assistant Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers,
and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Acknowledgement

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Supported by an independent educational grant from Merck & Co., Inc.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191